XTRA:BAYNPharmaceuticals
Bayer Stroke Data Spotlight Shifts Focus Toward Asundexian Pipeline Potential
Bayer plans to present late breaking Phase III OCEANIC STROKE data for asundexian at the 2026 European Stroke Organisation Conference.
The company will share 13 abstracts, including subgroup analyses and real world stroke data, focused on its oral Factor XIa inhibitor program.
The presentations highlight progress in Bayer's stroke franchise and add detail on a key asset in its late stage pharmaceuticals pipeline.
Bayer, traded as XTRA:BAYN, is drawing fresh attention to its pharmaceuticals...